Split History
ETFs Holding ADMP »    ADMP Historical Stock Prices »
Video: What is a Stock Split?


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Adamis Pharmaceuticals is a pharmaceutical company. Co. is primarily focused on developing its specialty pharmaceutical products: Epinephrine Injection USP 1:1000 0.3mg Pre-Filled Single Dose Syringe to deliver a premeasured dose of epinephrine for the treatment of anaphylaxis; APC-5000 dry powder inhaler for the treatment of asthma and chronic obstructive pulmonary disease (COPD); APC-1000 inhaler product for asthma and COPD; and APC-2000 for the treatment or prevention of bronchospasm. Co. also has a number of biotechnology product candidates and technologies, including therapeutic vaccine and cancer product candidates and technologies such as TeloB-VAX (vaccine) for prostate cancer. According to our ADMP split history records, Adamis Pharmaceuticals has had 1 split.
ADMP split history picture
Adamis Pharmaceuticals (ADMP) has 1 split in our ADMP split history database. The split for ADMP took place on December 13, 2013. This was a 1 for 17 reverse split, meaning for each 17 shares of ADMP owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 58.8235294117647 share position following the split.

When a company such as Adamis Pharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share. Looking at the ADMP split history from start to finish, an original position size of 1000 shares would have turned into 58.8235294117647 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Adamis Pharmaceuticals shares, starting with a $10,000 purchase of ADMP, presented on a split-history-adjusted basis factoring in the complete ADMP split history. ADMP split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 05/29/2007
End date: 05/26/2017
Start price/share: $1.36
End price/share: $3.70
Dividends collected/share: $0.00
Total return: 172.06%
Average Annual Total Return: 10.53%
Starting investment: $10,000.00
Ending investment: $27,214.58
Years: 10.00
Date Ratio
12/13/20131 for 17
ADMP is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

ADMS Split History
ADPT Split History
ADXS Split History
AEZS Split History
AFAM Split History
AFFX Split History
AGN Split History
AHPI Split History
AIMT Split History
AIQ Split History

Yield10 Bioscience, Inc. (YTEN)
Xerox Corporation (XRX)
Waste Connections, Inc. (WCN)
Spark Energy, Inc. (SPKE)
MagneGas Corporation (MNGA)
Frontier Communications Corporation (FTR)
NeuroMetrix, Inc. (NURO)
Pain Therapeutics, Inc. (PTIE)
Rex Energy Corporation (REXX)
Rexahn Pharmaceuticals, Inc. (RNN)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

ADMP Insider Buying

ADMP Split History | www.SplitHistory.com | Copyright © 2013 - 2017, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.